Company: CERO
Filing Date: 2025-12-02
Form Type: DEFA14A
Source: 0001213900-25-117250
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-02
Form: DEFA14A
Chunk 2
---
 are considered to be “routine” under these rules, such that
your broker may vote your shares on this proposal in its discretion in the absence of your voting instructions. Conversely, Proposal Nos.
2 and 3 are considered to be “non-routine” under these rules such that your broker may not vote your shares on this proposal
in the absence of your voting instructions.

<div align='center'>1

CERO THERAPEUTICS HOLDINGS, INC.

201 Haskins Way, Suite 230

South San Francisco, CA 94080

VOTING MATTERS</div>

This Supplement to the Proxy
Statement does not change the proposals to be acted upon at the Special Meeting, which are described in the Proxy Statement.

You are urged to read the Proxy Statement and this Supplement carefully in deciding how to vote. As a stockholder, your vote is very important, and the
Board of Directors encourages you to exercise your right to vote whether or not you plan to attend the Special Meeting. If you have already
voted by Internet, telephone or by mail, you do not need to take any action unless you wish to change your vote. Proxy voting instructions
already returned by stockholders (via Internet, telephone or mail) will remain valid and will be voted at the Special Meeting unless revoked.

| By Order of the Board of Directors              |
| CERo Therapeutics Holdings, Inc.                |
| /s/ Chris Ehrlich                               |
| Chris Ehrlich                                   |
| Chairman, Chief Executive Officer  and Director |
| South San Francisco, California                 |
| December 2, 2025                                |

<div align='center'>2</div>